| Autor: |
Giuseppe Vergaro, Alberto Aimo, Francesco Gentile, Giulia Elena Mandoli, Marta Focardi, Vincenzo Castiglione, Alberto Giannoni, Giorgia Panichella, Alessandra Fornaro, Erberto Carluccio, Riccardo Liga, Mattia Salatin, Claudio Passino, Massimo F. Piepoli, Matteo Cameli, Francesco Cappelli, Carlo Di Mario, Michele Emdin |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
ESC Heart Failure, Vol 11, Iss 6, Pp 3523-3529 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2055-5822 |
| DOI: |
10.1002/ehf2.14767 |
| Popis: |
Abstract Aims Vericiguat is a soluble guanylate cyclase stimulator and improves survival in patients with heart failure (HF) with reduced ejection fraction (HFrEF) and an increased risk of decompensation. As real‐world data on how many patients could be eligible for vericiguat therapy derive from outdated registries, we aimed to assess eligibility in a prospective cohort of patients with HF. Methods and results Data from consecutive HF patients undergoing an elective ambulatory visit at five university hospitals from 3 July to 28 July 2023 were collected. Independent investigators assessed which patients (i) met the eligibility criteria of the VICTORIA trial, (ii) complied with HF guideline recommendations, (iii) met regulatory agency criteria, or (iv) met criteria for refundability according to the Italian regulatory agency. Patients (n = 346, 72% men, median age 69 years) had HFrEF in 57% of cases, left ventricular ejection fraction |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text